Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
July 22 2014 - 8:32PM
Business Wire
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty
pharmaceutical company focused on developing and commercializing a
portfolio of products for the critical care market, announced today
that the Company will host a conference call and live audio webcast
on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial
results for the fourth quarter and fiscal year ended April 30,
2014, and provide a corporate update.
To participate in the call, please dial 877‐407‐8029 (domestic)
or 201‐689‐8029 (international) and refer to conference ID
13585285. A live webcast of the call can be accessed under “Events
and Presentations” in the Investors section of the Company’s
website at www.oxybiomed.com.
An archived webcast recording will be available on the Oxygen
Biotherapeutics website beginning approximately two hours after the
call.
About Oxygen Biotherapeutics
Oxygen Biotherapeutics, Inc. is a specialty pharmaceutical
company focused on developing and commercializing a portfolio of
products for the critical care market. The company recently
acquired the North American rights to develop and commercialize
levosimendan, and the United States Food and Drug Administration
(FDA) has granted Fast Track status for levosimendan for the
reduction of morbidity and mortality in cardiac surgery patients at
risk for developing Low Cardiac Output Syndrome (LCOS). The company
plans to start a Phase 3 trial with levosimendan in that indication
during the third quarter of 2014, and has also developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called
Oxycyte® that is currently in clinical and preclinical studies for
intravenous delivery for indications such as traumatic brain
injury, decompression sickness and stroke.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the company that involve risks and uncertainties and reflect the
company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, matters beyond the company's control that
could lead to delays in the clinical study, delays in new product
introductions and customer acceptance of these new products, and
other risks and uncertainties as described in the company’s filings
with the Securities and Exchange Commission, including in its
quarterly report on Form 10-Q filed on March 17, 2014, and annual
report on Form 10-K filed on June 26, 2013, as well as its other
filings with the SEC. The company disclaims any intent or
obligation to update these forward-looking statements beyond the
date of this release. Statements in this press release regarding
management’s future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
Stern Investor RelationsJesse Baumgartner,
212-362-1200jesse@sternir.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Sep 2023 to Sep 2024